Publications, Posters and Presentations

Publications, Posters & Presentations 2021/22

Publications

ENZAMET Research Review, 1 May 2021

EDUCATIONAL SERIES – Enzalutamide in men with metastatic hormone-sensitive prostate cancer: focus on the ARCHES and ENZAMET trials.

Ian D . Davis

SUBDUE-1 BJU International, 6 May 2021

A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol

Andrew Moe, Elizabeth Liow, Andrew Redfern, Nicole Swarbrick, Tom Ferguson, Ian D . Davis, Dickon Hayne

ENZAMET European Urology, 22 May 2021

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin M Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, M Neil Reaume, Shahneen K Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott G Williams, Sonia Yip, Alison Y Zhang, Robert R Zielinski, Ian D Davis, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

ENZA-p BJU International, 24 May 2021

ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Rana, Ailsa Langford, Jenna Mitchell, Sonia Yip, Roslyn Francis, Michael S . Hofman, Shahneen Sandhu, Arun Azad, Craig Gedye, Margaret McJannett, Martin R . Stockler, and Ian D . Davis on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and the ENZA-p investigators .

Pain Free TRUS-B BJU International, 17 July 2021

‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)

Dickon Hayne, Jeremy Grummet, David Espinoza, Steve P . McCombie, Venu Chalasani, Kate S . Ford, Mark Frydenberg, Peter Gilling, Barbara Gordon, Cynthia Hawks, Alex Konstantatos, Andrew J . Martin, Anthony Nixon, Colin O’Brien, Manish I . Patel, Shomik Sengupta, Shekib Shahbaz, Shalini Subramaniam, Scott Williams, Henry H . Woo, Martin R . Stockler, Ian D . Davis, Nick Buchan, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

TheraP BMJ Journals, 9 August 2021

Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: patient experiences

Bianca Viljoen, Michael S Hofman, Suzanne K Chambers, Jeff Dunn, Haryana Dhillon, Ian D Davis and Nicholas Ralph

RAMPART Contemporary Clinical Trials, 21 September 2021

RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Bhavna Oza, Eleni Frangou, Ben Smith, Hanna Bryant, Rick Kaplan, Babak Choodari-Oskooei, Tom Powles, Grant D . Stewart, Laurence Albiges, Axel Bex, Toni K . Choueiri, Ian D . Davis, Tim Eisen, Alison Fielding, David Harrison, Anita McWhirter, Salena Mulhere, Paul Nathan, Brian Rini, Alastair Ritchie, Sarah Scovell, Clare Shakeshaft, Martin R . Stockler, Nat Thorogood, Mahesh K . B . Parmar, James Larkin, Angela Meade

ENZAMET European Urology, 30 September 2021

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Sweeney, C . J .; Martin, A . J .; Stockler, M . R .; Begbie, S .; Chi, K . N .; Chowdhury, S .; Coskinas, X .; Frydenberg, M .; Hague, W . E .; Horvath, L . G .; Joshua, A . M .; Lawrence, N . J .; Marx, G . M .; McCaffrey, J .; McDermott, R .; McJannett, M .; North, S . A .; Parnis, F .; Parulekar, W .; Pook, D . W .; Reaume, M . N .; Sandhu, S . K .; Tan, A .; Tan, T . H .; Thomson, A .; Tu, E .; Vera-Badillo, F .; Williams, S . G .; Yip, S .; Zhang, A . Y .; Zielinski, R . R .; Davis, I . D .; Investigators, Enzamet Trial; the, Australian; New Zealand, Urogenital; Prostate Cancer Trials, Group

ExerciseGuide Cancer, 25 November 2021

Acceptability and Preliminary Efficacy of a Web- and Telephone-Based Personalised Exercise Intervention for Individuals with Metastatic Prostate Cancer: The ExerciseGuide Pilot Randomised Controlled Trial

Holly E . L . Evans, Daniel A . Galvão, Cynthia C . Forbes, Danielle Girard, Corneel Vandelanotte, Robert U . Newton, Andrew D . Vincent, Gary Wittert, Ganessan Kichenadasse, Suzanne Chambers, Nicholas Brook and Camille E . Short

ENZAMET Journal of Clinical Oncology, 20 December 2021

Health-Related Quality of Life in Metastatic, HormoneSensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Martin R . Stockler, Andrew J . Martin, Ian D . Davis, Haryana M . Dhillon, Stephen D . Begbie, Kim N . Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E . Hague, Lisa G . Horvath, Anthony M . Joshua, Nicola J . Lawrence, Gavin M . Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A . North, Francis Parnis, Wendy R . Parulekar, David W . Pook, M . Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G . Williams, Diana G . Winter, Sonia Yip, Alison Y . Zhang, Robert R . Zielinski, and Christopher J . Sweeney

Poster Presentations

ASCO 2021: Virtual Meeting, 4 June 2021 – 8 June 2021 UNISoN (ANZUP 1602) Abstract #4565

Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma

First Author: Craig Gedye

ASCO GU 2022: Virtual Meeting, 17-19 February 2022 ENZA-p (ANZUP 1901) Abstract # TPS205

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

First Author: Louise Emmett

DASL-HiCaP (ANZUP 1801) Abstract # 352254

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate –a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801)

First Author: S M McBride

SUBDUE-1 Abstract #483

SUB-urothelial Durvalumab InjEction – 1 (SUBDUE-1) – Results from the first nine urothelial cancer patients using a doseescalation schedule

First Author: Dickon Hayne

TheraP (ANZUP 1603) Abstract # 356724

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).